Jake Shuman serves as the Head of Transactions and M&A for Corporate Business Development at Eli Lilly and Company. His expertise is in strategic acquisitions and transactions, particularly within the field of genetic medicine, stemming from his previous leadership roles at Prevail Therapeutics. He holds a bachelors degree from Amherst College.
He played a key role in the successful acquisition of his former company, gene therapy pioneer Prevail Therapeutics, by his current employer, Eli Lilly and Company.